Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Barclays PLC

Barclays PLC grew its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 294.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,438 shares of the biotechnology company’s stock after purchasing an additional 20,478 shares during the quarter. Barclays PLC owned approximately 0.13% of Enanta Pharmaceuticals worth $285,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. bought a new position in Enanta Pharmaceuticals during the 3rd quarter worth $122,000. Geode Capital Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after acquiring an additional 14,575 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of Enanta Pharmaceuticals by 65.8% during the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock worth $588,000 after acquiring an additional 18,003 shares during the last quarter. American Century Companies Inc. grew its position in shares of Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock worth $362,000 after acquiring an additional 7,287 shares during the last quarter. Finally, Erste Asset Management GmbH acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter worth about $1,243,000. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Trading Up 8.2 %

Shares of NASDAQ:ENTA opened at $5.25 on Tuesday. The company has a 50 day moving average of $7.12 and a 200-day moving average of $10.65. The firm has a market cap of $111.27 million, a P/E ratio of -0.96 and a beta of 0.56. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.71 and a twelve month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, November 25th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). The firm had revenue of $14.60 million during the quarter, compared to analyst estimates of $17.99 million. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. The business’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter last year, the company earned ($1.33) earnings per share. Equities research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.93 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JMP Securities restated a “market outperform” rating and issued a $21.00 target price (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th. HC Wainwright reduced their price objective on Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, December 24th. Finally, Robert W. Baird lowered their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 26th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $17.25.

Insider Activity

In other news, CEO Jay R. Luly sold 5,142 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $8.06, for a total value of $41,444.52. Following the transaction, the chief executive officer now owns 801,638 shares of the company’s stock, valued at $6,461,202.28. The trade was a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 13.64% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.